Exicure Announces New CEO and Interim CFO Appointments

Exicure ( (XCUR) ) just unveiled an update.

On February 11, 2026, Exicure, Inc. appointed Jung Soo Kim as Chief Executive Officer and President and named Gyuyeob Lee as Interim Chief Financial Officer and Secretary, following the February 9, 2026 resignations of former CEO and President Andy Yoo and former CFO and Secretary Seung Ik Baik. Kim brings more than 20 years of experience in corporate strategy, capital markets and restructuring, while Lee adds expertise in governance restructuring, financial planning and regulatory compliance, with both executives providing their services through agreements with Innocircle Advisors Inc., signaling a shift in Exicure’s leadership structure and potentially its strategic and financial direction.

The most recent analyst rating on (XCUR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Exicure stock, see the XCUR Stock Forecast page.

Spark’s Take on XCUR Stock

According to Spark, TipRanks’ AI Analyst, XCUR is a Neutral.

The score is primarily constrained by weak financial performance (minimal revenue, large losses, and still-negative cash flow) and bearish technicals (below key moving averages with negative MACD). Offsetting these risks are signs of stabilization in 2024, including reduced cash burn and improved leverage.

To see Spark’s full report on XCUR stock, click here.

More about Exicure

Exicure, Inc. operates in the biotechnology and life sciences sector, historically focusing on the development of nucleic acid–based therapeutics. The company targets innovative treatments leveraging advanced molecular and genomic technologies, positioning itself within a competitive segment of the biopharmaceutical and drug discovery market.

Average Trading Volume: 717,451

Technical Sentiment Signal: Sell

Current Market Cap: $26.01M

Find detailed analytics on XCUR stock on TipRanks’ Stock Analysis page.